Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 5/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337653 | 0.94 | GPR119 (0.41) | CTSATDP1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4337632 | 0.94 | CTSA (0.44) | CTSA | |
| SCHEMBL4322072 | 0.92 | CTSA (0.40) | CTSAMMP8KDM4ETDP1ALDH1A1 | |
| SCHEMBL4335078 | 0.91 | CTSA (0.38) | CTSATDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4341790 | 0.90 | CTSA (0.40) | CTSAMMP8KDM4ETDP1ALDH1A1 | |
| SCHEMBL4333232 | 0.89 | CTSA (0.40) | CTSA | |
| SCHEMBL4323851 | 0.88 | CTSA (0.39) | CTSAKDM4ETDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4322302 | 0.87 | CTSA (0.38) | CTSA | |
| SCHEMBL4343412 | 0.86 | FFAR1 (0.42) | CTSAALDH1A1L3MBTL1GAA | |
| SCHEMBL4328657 | 0.83 | MMP1 (0.38) | CTSAMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521563-B2 | Hydroxamic acid derivative and medicine containing the same as active ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | IL6, IL1A, TNF | CTSA 1028/4885MMP8 132/4885KDM4E 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.